PROTECT-CHILDREN
In a groundbreaking new study, alarming insights are unveiled about the technology platforms that offenders use to sexually abuse children online. The research surveyed over 30,000 online child sexual abuse material (CSAM) offenders and uncovers significant information to tackle the proliferation of online child sexual abuse and exploitation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220388317/en/
In a groundbreaking new study, alarming insights are unveiled about the technology platforms that offenders use to sexually abuse children online. Photo: Protect Children
The research reveals that 40% of CSAM offenders have attempted to contact a child. 70% of them sought contact with a child online, mainly through social media, online gaming, or messaging platforms, with Instagram, Facebook, and Discord being the most exploited social media platforms. End-to-end encrypted messaging apps, Telegram, WhatsApp, and Signal were highlighted as common tools for these illicit activities. These messaging apps are favoured by offenders due to the security and privacy offered by end-to-end encryption, which allows them to commit crimes without fear of detection.
On 20 February, Protect Children will present the research for the first time at the European Parliament. The event will facilitate an active dialogue with policymakers and tech industry representatives on the urgent need for tech to step up efforts to tackle online child sexual abuse and exploitation.
Tech industry must step up their efforts to keep children safe online
In response to these findings, Protect Children has outlined a series of actionable recommendations for the tech industry to step up efforts to combat online child sexual exploitation and abuse. These include adopting a children's rights-by-design approach in platform development, enhancing detection and removal of CSAM, and ensuring stringent age verification processes.
Protect Children urges tech companies not to implement end-to-end encryption on their services without appropriate safeguards to ensure access to evidence by law enforcement and maintain the ability to detect and report CSAM.
The research was conducted with the support of Safe Online. However, the opinions, findings, conclusions, and recommendations expressed are those of the author Protect Children and do not necessarily reflect those of Safe Online.
Read the full press release here: https://www.suojellaanlapsia.fi/en/post/press-release-200224
Read the research report: https://www.suojellaanlapsia.fi/en/post/tech-platforms-child-sexual-abuse
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220388317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model4.11.2025 16:48:00 CET | Press release
Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE)Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE)Synergistic Cytotoxicity: NaN and ABE together decreased cell proliferation by 60% in vitro, suggesting synergistic effectsNo Tumor Activity: Histology revealed no ki67 staining and increased necrosis in Zeta-BC-007-treated tumorsImmune Activation: Treated mice showed elevated macrophage infiltration and increased circulating monocytes Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME
A New Era Begins: Visionaries Unite to Shape the Next 50 Years of Tourism at TOURISE4.11.2025 16:35:00 CET | Press release
More than 120 global leaders will convene in Riyadh for the inaugural TOURISE Summit this November, bringing together the largest cross-sector gathering covering all industries that benefit from the trillion dollar tourism sector. From sports, entertainment, media, transport and aviation; representatives from government, business and non-profits will join Expedia, Google, Amadeus, Accor, Nikki Beach, Red Sea Global, Certares and the Public Investment Fund (PIF). From headline panels and visionary keynotes to fireside chats and immersive sessions, TOURISE will spotlight the forces transforming global tourism, and the ideas shaping what comes next for the future of tourism. Get ready to witness history in the making. Over three electrifying days, across two dynamic stages, more than 120 of the world’s most influential visionaries, change-makers, and industry pioneers will converge at the inaugural TOURISE Summit – the boldest global platform designed to unite governments, businesses, inv
Digital Access Reaches Four in Five People Worldwide, DCO’s DEN 2025 Finds4.11.2025 16:35:00 CET | Press release
The Digital Cooperation Organization (DCO), the international organization dedicated to advancing inclusive and sustainable digital economies, today launched the Digital Economy Navigator (DEN) 2025 at the Second World Summit for Social Development (WSSD2) in Doha. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104849013/en/ From left to right: H.E. Deemah AlYahya, Secretary General of the Digital Cooperation Organization - H.E. Imaan Sulaiman Ibrahim, Honorable Minister of Women Affairs and Social Development, Federal Republic of Nigeria - Alaa Abdulaal, Chief of Digital Economy Insight at the Digital Cooperation Organization. (Photo: AETOSWire) The second edition of the Navigator provides the most comprehensive analysis to date of global digital-economy maturity. Covering 80 countries representing 94 per cent of global GDP and 85 per cent of the world’s population, the report draws on 145 indicators and a survey of more
GEOLOG Unveils the KickMaster™ Flow-Meter Family for Extreme Well Conditions4.11.2025 16:33:00 CET | Press release
Patented instruments deliver reliable Flow-In/Flow-Out, density, and temperature data in high gas-cut and solids-laden muds for onshore and deepwater operations GEOLOG, the largest independent surface-logging company and a pioneer in applying AI to formation evaluation and automated drilling performance, today announced the immediate availability of KickMaster™, a patented family of flow meters engineered to provide accurate, real-time measurements in the most demanding drilling environments. Developed by GEOLOG’s in-house R&D team, KickMaster™ addresses long-standing challenges in measuring heterogeneous mud flows. The system delivers reliable flow, density, and temperature data during critical drilling events, enabling faster detection, better decision-making, and improved well control. Three engineered models for precise flow managementFlow-Out Meter - For standard and high-volume mud returns. Operates reliably with >40% gas in mud and introduces ~70% lower backpressure than typical
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium4.11.2025 16:04:00 CET | Press release
Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRIFirst-of-its-kind single intratumoral injection for MBC to the spineTreated lesions showed full bone regeneration with reconstitution of trabecular bone, and no skeletal related events; mean lesion defect volume decreased by 87.9% at day 180.Therapeutic spread extended to nearby non-treated lesions, also achieving complete response within the same vertebral body Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 10, 2025. The abstract
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom